tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 184 are a BUY (93.88%), 12 are a HOLD (6.12%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 30.61% that have a potential upside of 50.87% achieved within 152 days.
Ross Osborn’s has documented 378 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PRE, Prenetics Global Ltd at 10-Nov-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 04-Jan-2019
$1.35
$-0.38 (-21.97%)
1 months 11 days ago
(09-Sep-2026)
3/3 (100%)
$0.06 (4.65%)
131
Sell Since 14-Apr-2026
$1.5
$-0.15 (-9.09%)
$1
5 months 9 days ago
(11-May-2026)
5/8 (62.5%)
$0.14 (10.29%)
25
Buy Since 01-Jun-2020
$3
$1.27 (73.41%)
$3
7 months 1 days ago
(19-Mar-2026)
7/19 (36.84%)
$1.6 (114.29%)
133
Hold Since 16-May-2022
$2
$0.35 (21.21%)
$1.5
11 months 9 days ago
(11-Nov-2025)
13/14 (92.86%)
$0.14 (7.53%)
98
Buy Since 18-Feb-2025
$2
$0.35 (21.21%)
$1.8
11 months 10 days ago
(10-Nov-2025)
3/3 (100%)
$0.24 (13.64%)
150
What Year was the first public recommendation made by Ross Osborn?
